Research programme: antisense oligonucleotide therapeutics - AUM LifeTech/McGill University
Latest Information Update: 13 Apr 2023
At a glance
- Originator AUM LifeTech; McGill University
- Developer McGill University
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 13 Apr 2023 Discontinued for COVID-2019 infections in Canada, USA (Parenteral) (AUM LifeTech pipeline; April 2023)
- 07 May 2020 Antisense oligonucleotide therapeutics - AUM LifeTech/McGill University is available for licensing as of 07 May 2020. https://aumlifetech.com/COVID-19/
- 07 May 2020 AUM LifeTech has patent protection for FANA-ASO technology in USA, European Union, China, Singapore and Canada, prior May 2020